Home  /  Resource Library  /  Treatment with ublituximab plus ibrutinib versus ibrutinib alone: A phase III randomised trial (GENUINE) for patients with relapsed or refractory high-risk CLL

Treatment with ublituximab plus ibrutinib versus ibrutinib alone: A phase III randomised trial (GENUINE) for patients with relapsed or refractory high-risk CLL

Results of a phase III study examining ublituximab combined with ibrutinib for treatment of relapsed CLL.